Table 5.

Summary of the reactivity against CSC or FBS tumor cell lines by T lymphocytes isolated from GBM patients

Patient no.T-cell line no.Autologous CSC recognitionAutologous FBS tumor cell recognitionMHC restriction*Cytokine releaseTH type subset
0701042+++NAMHC IIFN-γTH1
0803251++++MHC IIIL-5TH2
0801254+++MHC IIIL-5TH2

NOTE: +, ≥ 50 < 100 spots/4 × 104 T cells; ++, ≥ 100 < 200 spots/4 × 104 T cells; +++, ≥ 200 < 800 spots/4 × 104 T cells; −, no inhibition was observed following preincubation of target cells with anti-HLA class I (W6/32) or HLA class II (L243) mAbs. These results have been obtained by thrice repeated ELISOPT assays, starting from the 3rd until the 6th week of culture. These were consistent throughout the repeated experiments, and the means of cytokine release and SD (≤10%) have been calculated; moreover, statistical analysis of differences between means of IFN-γ or IL-5 released by T cells was performed by two-tailed t test (data not shown).

Abbreviation: NA, FBS tumor cells were not available.

  • *MHC restriction was evaluated by assessment of inhibition of cytokine release by T cells following coculture with either autologous GBM CSC or FBS tumor cells preincubated with anti-HLA class I (W6/32) or HLA class II (L243) mAbs.

  • Recognition by T lymphocytes of autologous CSC or FBS tumor cells was assessed by cytokine release (IFN-γ or IL-5) using ELISPOT.